-
Je něco špatně v tomto záznamu ?
Influence of BAKs on tear film lipid layer: In vitro and in silico models
K. Riedlová, MC. Saija, A. Olżyńska, P. Jurkiewicz, P. Daull, JS. Garrigue, L. Cwiklik
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
- MeSH
- benzalkoniové sloučeniny škodlivé účinky MeSH
- konzervační prostředky farmaceutické * farmakologie MeSH
- lidé MeSH
- lipidy farmakologie MeSH
- oční roztoky MeSH
- slzy MeSH
- syndromy suchého oka * farmakoterapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Benzalkonium chloride (BAK) compounds are commonly used in topical ophthalmic products as preservatives and stabilizers. BAK mixtures containing several compounds with different alkyl chain lengths are typically used. However, in chronic eye conditions, such as dry eye disease and glaucoma, the accumulation of adverse effects of BAKs was observed. Hence, preservative-free eye drops formulations are preferred. On the other hand, selected long-chain BAKs, particularly cetalkonium chloride, exhibit therapeutic functions, promoting epithelium wound healing and tear film stability. Nevertheless, the mechanism of BAKs influence on the tear film is not fully understood. By employing in vitro experimental and in silico simulation techniques, we elucidate the action of BAKs and demonstrate that long-chain BAKs accumulate in the lipid layer of the tear film model, stabilizing it in a concentration-dependent fashion. In contrast, short-chain BAKs interacting with the lipid layer compromise the tear film model stability. These findings are relevant for topical ophthalmic drug formulation and delivery in the context of selecting proper BAK species and understanding the dose dependency for tear film stability.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23011568
- 003
- CZ-PrNML
- 005
- 20230801133140.0
- 007
- ta
- 008
- 230718s2023 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejpb.2023.03.007 $2 doi
- 035 __
- $a (PubMed)36933811
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Riedlová, Kamila $u J. Heyrovský Institute of Physical Chemistry, Czech Academy of Sciences, Dolejškova 3, 18223 Prague, Czech Republic; Department of Physical and Macromolecular Chemistry, Faculty of Science, Charles University, Hlavova 8, 12800 Prague, Czech Republic
- 245 10
- $a Influence of BAKs on tear film lipid layer: In vitro and in silico models / $c K. Riedlová, MC. Saija, A. Olżyńska, P. Jurkiewicz, P. Daull, JS. Garrigue, L. Cwiklik
- 520 9_
- $a Benzalkonium chloride (BAK) compounds are commonly used in topical ophthalmic products as preservatives and stabilizers. BAK mixtures containing several compounds with different alkyl chain lengths are typically used. However, in chronic eye conditions, such as dry eye disease and glaucoma, the accumulation of adverse effects of BAKs was observed. Hence, preservative-free eye drops formulations are preferred. On the other hand, selected long-chain BAKs, particularly cetalkonium chloride, exhibit therapeutic functions, promoting epithelium wound healing and tear film stability. Nevertheless, the mechanism of BAKs influence on the tear film is not fully understood. By employing in vitro experimental and in silico simulation techniques, we elucidate the action of BAKs and demonstrate that long-chain BAKs accumulate in the lipid layer of the tear film model, stabilizing it in a concentration-dependent fashion. In contrast, short-chain BAKs interacting with the lipid layer compromise the tear film model stability. These findings are relevant for topical ophthalmic drug formulation and delivery in the context of selecting proper BAK species and understanding the dose dependency for tear film stability.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a konzervační prostředky farmaceutické $x farmakologie $7 D011310
- 650 _2
- $a benzalkoniové sloučeniny $x škodlivé účinky $7 D001548
- 650 _2
- $a slzy $7 D013666
- 650 12
- $a syndromy suchého oka $x farmakoterapie $7 D015352
- 650 _2
- $a oční roztoky $7 D009883
- 650 _2
- $a lipidy $x farmakologie $7 D008055
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Saija, Maria Chiara $u J. Heyrovský Institute of Physical Chemistry, Czech Academy of Sciences, Dolejškova 3, 18223 Prague, Czech Republic; Department of Physical and Macromolecular Chemistry, Faculty of Science, Charles University, Hlavova 8, 12800 Prague, Czech Republic
- 700 1_
- $a Olżyńska, Agnieszka $u J. Heyrovský Institute of Physical Chemistry, Czech Academy of Sciences, Dolejškova 3, 18223 Prague, Czech Republic
- 700 1_
- $a Jurkiewicz, Piotr $u J. Heyrovský Institute of Physical Chemistry, Czech Academy of Sciences, Dolejškova 3, 18223 Prague, Czech Republic
- 700 1_
- $a Daull, Philippe $u SANTEN SAS, Novagali Innovation Center, 1 rue Pierre Fontaine, Bâtiment Genavenir IV, CEDEX F-91458 Evry, France
- 700 1_
- $a Garrigue, Jean-Sebastien $u SANTEN SAS, Novagali Innovation Center, 1 rue Pierre Fontaine, Bâtiment Genavenir IV, CEDEX F-91458 Evry, France
- 700 1_
- $a Cwiklik, Lukasz $u J. Heyrovský Institute of Physical Chemistry, Czech Academy of Sciences, Dolejškova 3, 18223 Prague, Czech Republic. Electronic address: lukasz.cwiklik@jh-inst.cas.cz
- 773 0_
- $w MED00001640 $t European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V $x 1873-3441 $g Roč. 186, č. - (2023), s. 65-73
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36933811 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801133136 $b ABA008
- 999 __
- $a ok $b bmc $g 1963786 $s 1197833
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 186 $c - $d 65-73 $e 20230316 $i 1873-3441 $m European journal of pharmaceutics and biopharmaceutics $n Eur J Pharm Biopharm $x MED00001640
- LZP __
- $a Pubmed-20230718
